The Use of EPID-based in vivo Dosimetry for Small Animal Radiation Research

Creative Commons License


Türk Onkoloji Dergisi, vol.38, no.2, pp.201-208, 2023 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 2
  • Publication Date: 2023
  • Doi Number: 10.5505/tjo.2023.3855
  • Journal Name: Türk Onkoloji Dergisi
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.201-208
  • Keywords: Electronic portal imaging device, in vivo dosimetry, preclinical radiotherapy
  • Hacettepe University Affiliated: Yes


OBJECTIVE To validate the feasibility of electronic portal imaging device (EPID)- based in vivo dosimetry system for the verification of small animal radiation research METHODS The workflow can be divided into three steps. In the first part, external body of the rat phantom was modeled based on the computed tomography (CT) dataset of a real rat previously scanned for another radiobiological experiment and the structure set was exported to 3D Slicer program to convert DICOM file to. stl file format. Tissue-equivalent rat phantom was, then, printed using Makerbot Replicator Z18 3D-printer. In the second part, treatment plans were created for different anatomical sites including whole brain and total lung irradiation using Elekta Versa HD linear accelerator. In the last part, measurements were performed with EPID-based 3D in vivo dosimetry system. During the analysis, 3D γ analysis method was used and γ evaluation criteria were set to 3 mm distance-to-agreement and 3% dose differences for local dose. RESULTS According to our analysis, EPID measurement for each modality and anatomical site met the protocol value except for % γ≤1 and γ mean values for total lung irradiation, but both of these parameters met the proposed minor variation criteria. CONCLUSION Implementation of EPID-based 3D in vivo dosimetry for preclinical radiation research with small animals seems to be feasible.